Novel Disease but responding to an Old Drug: Role of Prolonged Corticosteroid Use in Prevention and Treatment of Post-Covid Interstitial Lung Disease (PC-ILD)

  • Muhammad Waseem Sahiwal Medical College, Sahiwal
  • Maryam Rafiq Sahiwal Medical College, Sahiwal
Keywords: Anti-fibrotic, Fibrosis, Post-COVID sequalae, Post-COVID fibrosis, Post-COVID ILD

Abstract

Coronavirus has affected more than 128 million humans worldwide with invasion in 129 countries across the globe. About 5-10 percent of these patients have pulmonary involvement in the form of COVID Pneumonia leading to ARDS. Although there are no statistics at the moment, trends show that majority will get rid of acute COVID respiratory involvement without any long-term pulmonary complications however several patients will face COVID sequel in the form of post-COVID fibrosis or post-COVID interstitial lung disease. With more and more survivors of COVID-19, long-term pulmonary complications of this infection especially Post-COVID ILD are being recognized by treating physicians which have a great impact on patient’s functionality and quality of life. Since there is no research-based internationally accepted strategy to prevent and treat Post-COVID ILD, a strategy based upon observations of treating pulmonologists was devised in the COVID management unit Sahiwal Medical College Sahiwal to prevent and treat Post COVID interstitial lung disease.

 

Key Words

 Anti-fibrotic, Fibrosis, Post-COVID sequalae, Post-COVID fibrosis, Post-COVID ILD

Author Biography

Muhammad Waseem, Sahiwal Medical College, Sahiwal

Assistant Professor& HOD Pulmonology

Sahiwal Medical College, Sahiwal

References

1- Myall KJ, Mukherjee B, Castanheira AM, Lam JL, Benedetti G, Mak SM, Preston R, Thillai M, Dewar A, Molyneaux PL, West AG. Persistent Post–COVID-19 Interstitial Lung Disease. An Observational Study of Corticosteroid Treatment. Annals of the American Thoracic Society. 2021 May;18(5):799-806.
2- Ambardar SR, Hightower SL, Huprikar NA, Chung KK, Singhal A, Collen JF. Post-COVID-19 Pulmonary Fibrosis: Novel Sequelae of the Current Pandemic. Journal of Clinical Medicine. 2021 Jan;10(11):2452.
3- Udwadia ZF, Koul PA, Richeldi L. Post-COVID lung fibrosis: The tsunami that will follow the earthquake. Lung India. 2021 Mar 1;38(7):41.
4- Wells AU, Devaraj A, Desai SR. Interstitial Lung Disease after COVID-19 Infection: A Catalog of Uncertainties.
5- Yu M, Liu Y, Xu D, Zhang R, Lan L, Xu H. Prediction of the development of pulmonary fibrosis using serial thin-section CT and clinical features in patients discharged after treatment for COVID-19 pneumonia. Korean journal of radiology. 2020 Jun;21(6):746.
6- Wise J, Coombes R. Covid-19: The inside story of the RECOVERY trial. BMJ. 2020 Jul 8;370.
Published
2022-06-30
How to Cite
1.
Waseem M, Rafiq M. Novel Disease but responding to an Old Drug: Role of Prolonged Corticosteroid Use in Prevention and Treatment of Post-Covid Interstitial Lung Disease (PC-ILD). JRMC [Internet]. 30Jun.2022 [cited 12Aug.2022];26(2):165-8. Available from: https://journalrmc.com/index.php/JRMC/article/view/1786
Section
Short Communication